Isis Pharmaceuticals to License Anti-Clotting Drug to Bayer
May 04 2015 - 06:48PM
Dow Jones News
By Chelsey Dulaney
Isis Pharmaceuticals Inc. (ISIS) has agreed to license its
experimental anticlotting drug to a Bayer AG (BAYRY, BAYN.XE) unit
for an initial payment of $100 million.
Bayer HealthCare will develop and commercialize the drug. Bayer
plans to evaluate the drug, ISIS-FXI, in patients who can't use
anticoagulants, such as patients with a high risk of bleeding.
Bayer said the drug complements its pipeline of thrombosis
treatments. Thrombosis is a process involving blood-clot formation
that can result in heart attacks and strokes.
Isis Pharmaceuticals is also eligible for a $55 million payment
after a phase-two study in patients with compromised kidney
function. The company will also be eligible for milestone payments
and royalties.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Bayer (TG:BAYN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Mar 2023 to Mar 2024